Background: Triclosan is a widely applied antimicrobial agent which affects the endocrine system and homeostasis; it may also promote the cirrhosis and hepatocellular carcinoma (HCC) growth in a mice model. The exact roles of triclosan in regulating human hepatocellular carcinoma development and treatment remain unknown. Methods: MHCC97-H, a highly aggressive HCC cell line, was treated with indicated concentration of triclosan or sorafenib. The expression of drug-resistance genes was examined by qPCR. The clearance or metabolism of sorafenib was determined by liquid chromatograph-mass spectrometer/mass spectrometer (LC-MS/MS). MTT assay was used to examine the MHCC97-H cell proliferation. Nude mice were used to exam the anti-tumor effect of sorafenib on subcutaneous and intrahepatic growth of MHCC97-H cells. Results: In the present study, triclosan could induce the expression of drug-resistance genes in MHCC97-H cells (a highly aggressive HCC cell line), accelerate the clearance of sorafenib, and attenuate the anti-proliferation effect of this molecular targeted agent in MHCC97-H cells. Triclosan decreased the antitumor effect of sorafenib on subcutaneous and intrahepatic growth of MHCC97-H in nude mice. Conclusion: By discovering the fact that triclosan treatment enhances sorafenib resistance in HCC cells, this work suggests exposure of triclosan is detrimental to HCC patients during chemotherapy.
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Introduction
Hepatocellular carcinoma (HCC) is one of the most common human malignancies in China that partially attributes to the large hepatitis virus (hepatitis B virus or hepatitis C virus) carriers population. 1, 2 Because of the limitations of current clinical diagnosis options, most patients were found to have advanced HCC even at their initial diagnosis, which is no longer suitable for liver transplant or surgical operation. 3, 4 Advanced HCC patients could not be clinically benefited from systemic chemotherapies and molecular targeting therapies, for example, the first-line agent sorafenib and the second-line agent Regorafenib. 5, 6 About 30%-40% of patients are initially insensitive to sorafenib, whereas some patients with good initial responses become resistant to sorafenib as the therapy progressed. 7 Until now, the mechanism of sorafenib resistance remains unclear. Triclosan (TCS, 5-chloro-2-(2,4-dichlorophenoxy) phenol) is an antimicrobial agent widely used in general consumer products for personal care and household cleaning. 8 Initially, TCS was considered as well tolerated and safe. However, TCS was recently found to affect endocrine and impair muscle contraction. 9 In 2014, Yueh et al reported that TCS could promote the progress of cirrhosis and HCC in mice model. 10 However, the exact role of TCS in HCC regulation or treatment is still largely unknown. In present work, TCS is showed to induce the expression of drug-resistance genes and promote Total rna isolation and quantitative polymerase chain reaction (qPcr)
MHCC97-H cells were treated with indicated concentrations of TCS (0, 30, 100, 300, and 1,000 nmol/L) for 48 hours. Then, cells were harvested, and RNA extracting and qPCR experiments were performed following protocols described previously. 13, 14 The expression of drug resistance-related gene within MHCC97-H cells was examined by qPCR with primers listed in Table 1 . The mRNA level of drug resistancerelated genes from qPCR was analyzed by cluster analysis using SPSS software.
growth inhibition assay of hcc cells MHCC97-H cells, which were pretreated with solvent control or 300 nmol/L TCS (the maximum-effect concentration for TCS to induce the expression of drug resistance-related genes without cell toxicity), were cultured with sorafenib for specified concentrations and time points. The concentration of sorafenib varies from 0.01 to 10 μmol/L, and the treating time points range from 0 to 72 hours. 16, 17 Tumor size was monitored every 3 days by measuring length and width with a caliper, the tumor volumes were calculated as length × width × width/2.
4 After 2-3 weeks' growth, when tumors reached 1,000-1,200 mm 3 volume, mice were randomly divided into four groups and treated as follows: 1) mice were used as control group; 2) mice were injected intravenously with 500 μg/kg TCS (per day); 3) mice were administered 3 mg/kg oral sorafenib (per 2 days); and 4) mice were injected intravenously with 500 μg/kg TCS (per day) and administered 3 mg/kg oral sorafenib 
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Triclosan enhances sorafenib resistance in hcc (per 2 days) treatment. After 3 weeks treatment, all mice were sacrificed and the final volume of tumors was measured. Every group contains 10 animals, and similar results were obtained from three repeats.
For intrahepatic model, MHCC97-H cells were directly inoculated into the right lobe of mice liver (1 × 10 5 cells per animal). 20, 21 After 21 days, 20,21 nude mice were randomly divided to four groups: 1) mice were used as control group; 2) mice were injected intravenously with 500 μg/kg TCS (per day); 3) mice were administered 3 mg/kg oral sorafenib (per 2 days); and 4) mice were injected intravenously with 500 μg/ kg TCS (per day) and administered 3 mg/kg oral sorafenib (per 2 days) treatment. After 3 weeks treatment, all mice were injected intravenously with 400 μCi of 18 F radiolabeled fluorodeoxyglucose ( 18 F-FDG) and were examined by a positron emission tomography/computed tomography (PET/CT) scanner (Philips Corp., Holland, the Netherlands) as described by Xu et al. 21 An NaI (Tl) well counter (China Atom Corp., Beijing, China) was used to measure the radioactivity of organs (liver) to control (blood). 20, 21 Every group contains six animals, and similar results were obtained from three repeats.
clearance of sorafenib
To examine whether TCS could accelerate the metabolism or clearance of sorafenib in HCC cells, the clearance curve of sorafenib in HCC cells or tumors was determined. For cell- Forward primer 5′-ccgTgTacTccaacgcTgacaT-3′ reverse primer 5′-aTgcTgTgcgTgaccaagaTcc-3′ aBcc2 (aTP-binding cassette subfamily c member 2)
Forward primer 5′-gccaacTTgTggcTgTgaTagg-3′ reverse primer 5′-aTccaggacTgcTgTgggacaT-3′ aBcc3 (aTP-binding cassette subfamily c member 3)
Forward primer 5′-gaggagaaagcagccaTTggca-3′ reverse primer 5′-TccaaTggcagccgcacTTTga-3′ aBcg2 (aTP-binding cassette subfamily g member 2)
Forward primer 5′-gTTcTcagcagcTcTTcggcTT-3′ reverse primer 5′-TccTccagacacaccacggaTa-3′ aDra2a (adrenoceptor α2a)
Forward primer 5′-ccagggcacTcagaaacc-3′ reverse primer 5′-aaacgacgacaTagagggacT-3′ alDh1a1 (aldehyde dehydrogenase 1 family)
Forward primer 5′-acagggTcTacTgaggTTg-3′ reverse primer 5′-cTccacgaagaTgcgaga-3′ apo e (apolipoprotein e) Forward primer 5′-gaaTTcgccccgccTggTacac-3′ reverse primer 5′-TaagcTTggcacggcTgTccaagga-3′ cOMT (catechol-O-methyltransferase)
Forward primer 5′-TccTTcTcaacTgccaTTcc-3′ reverse primer 5′-ccTTagcgTTagcgTccgTc-3′ cYP1a2 (cytochrome P450 1a2)
Forward primer 5′-caTagccTcagaccccacaT-3′ reverse primer 5′-acaTTagccaccgaTTccac-3′ cYP2B6 (cytochrome P450 2B6)
Forward primer 5′-TcTggaTgccaaTggggcacTgaa-3′ reverse primer 5′-gggcgaTgccTTcaccaagacaaaTT-3′ cYP2c11 (cytochrome P450 2c11)
Forward primer 5′-gaggaccaTTgaggaccgTa-3′ reverse primer 5′-gagcacagcccaggaTaaag-3′ cYP2c19 (cytochrome P450 2c19)
Forward primer 5′-aacTacTTcaTgccTTTcTc-3′ reverse primer 5′-ggTccTTTgggTcaaTcag-3′ cYP2c22 (cytochrome P450 2c22)
Forward primer 5′-aTggggaTgggaaagagaac-3′ reverse primer 5′-TgcTggaaaaTgacacTgga-3′ cYP2c9 (cytochrome P450 2c9)
Forward primer 5′-cTTgacaccacTccagTTgTc-3′ reverse primer 5′-agaTggaTaaTgccccagag-3′ cYP2D6 (cytochrome P450 2D6)
Forward primer 5′-cTTcaccTcccTgcTgcag-3′ reverse primer 5′-Tcaccaggaaagcaaagaca-3′ cYP3a1 (cytochrome P450 3a1)
Forward primer 5′-aaaTgccTcTgTTTgccaTc-3′ reverse primer 5′-cTTTccccaTaaTccccacT-3′ cYP3a4 (cytochrome P450 3a4)
Forward primer 5′-ccccTgaaaTTaagcTTaggag-3′ reverse primer 5′-TaaTTTgaggTcTcTggTgTTcTca-3′ cYP3a5 (cytochrome P450 3a5)
Forward primer 5′-caTgacTTagTagacagaTgac-3′ reverse primer 5′-ggTccaaacagggaagaaaTa-3′
(Continued) 
) were cultured with sorafenib at IC 50 concentration (1 μmol/L) for 12 hours. Then, cells were divided into two groups and treated with solvent control or with 300 nmol/L concentration of TCS, separately. Cells were harvested at indicated time points and were lysed by sonication. Sorafenib in cells were extracted by acetonitrile (ACN) and quantitated using liquid chromatography/mass spectrometry-mass spectrometry (LC-MS/MS) as described in Allard et al, 18 He et al, 19 and Feng et al. 20 For subcutaneous tumor experiments, MHCC97-H cells were injected into nude mice to form subcutaneous tumors as mentioned above. Sorafenib (2 mg) was dissolved in a mixture of DMSO (10 μL), PEG400 (50 μL), and Tween 80 (30 μL). Then, sorafenib solution was carefully and slowly added with ddH 2 O to 1 mL total volume accompanied with ultrasonic or churning treatment. The final concentration of sorafenib in this solution is 2 mg/mL. Sorafenib containing solution (Sor-Sol) was injected into HCC subcutaneous tumors (20 μL per tumor). At indicated time points, tumor tissues were harvested, and the sorafenib was extracted by ACN. The amount of sorafenib was measured by LC-MS/MS. [18] [19] [20] statistical analysis
Statistical analysis was carried out using Bonferroni's correction with or without two-way analysis of variance in SPSS statistical software (IBM Corporation, Armonk, NY, USA 
Results
Triclosan enhances the expression of drug resistance-related genes in Mhcc97-h cells
To figure out whether TCS promotes sorafenib resistance process, the expression of drug resistance-related genes in TCS-treated MHCC97-H cells, a representative aggressive HCC cell line, was measured by qPCR. As shown in Figure 1 , 30 and 100 nmol/L of TCS could increase the expression of some CYPs or ATP-binding cassettes (ABCs; Cluster 1), and 300 nmol/L of TCS was the maximal effective concentration. TCS did not affect the expression of non-drug metabolism-related genes, such as ALDH1A1, Apo E, ADRA2A, DPYD, COMT, TPMT, HTRA, or methylenetetrahydrofolate reductase (MTHFR; Cluster 2). Moreover, as a result from cluster analysis, Figure 1 indicated the relations among these genes. CYPs or ABCs are Abbreviations: aBcc1, aTP-binding cassette subfamily c member 1; aBcc2, aTP-binding cassette subfamily c member 2; aBcc3, aTP-binding cassette subfamily c member 3; aBcg2, aTP-binding cassette subfamily g member 2; aDra2a, adrenoceptor α2a; alDh1a1, aldehyde dehydrogenase 1 family; apo e, apolipoprotein e; cOMT, catechol-O-methyltransferase; cYP1a2, cytochrome P450 1a2; cYP2c11, cytochrome P450 2c11; cYP2c22, cytochrome P450 2c22; cYP3a1, cytochrome P450 3a1; cYP3a4, cytochrome P450 3a4; cYP3a5, cytochrome P450 3a5; cYP2c19, cytochrome P450 2c19; DPYD, dihydropyrimidine dehydrogenase; hcc, hepatocellular carcinoma; hTr2a, 5-hydroxytryptamine receptor 2a; MThFr, methylenetetrahydrofolate reductase; qPcr, quantitative polymerase chain reaction; TPMT, thiopurine s-methyltransferase; UgT1a1, UDP glucuronosyltransferase family 1 member a1; UgT2B7, UDP glucuronosyltransferase family 2 member B7.
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Triclosan enhances sorafenib resistance in hcc listed in the same cluster, and there is no difference between the effect of TCS on CYPs, UDP glucuronosyltransferase family (UGTs), or ABCs. ALDH1A1, Apo E, ADRA2A, DPYD, COMT, TPMT, HTRA, or MTHFR was located in another cluster. Results from cluster analysis indicated that TCS mainly induced the expression of genes related to drug metabolism or clearance, and would induce UGT, CYPs, or ABCs by similar mechanisms in MHCC97-H cells. The cell viability after TCS treatment is shown in Figure 2 as TCS did not display cytotoxicity on MHCC97-H cells in tested concentration range. Interestingly, the higher concentrations of TCS would promote the proliferation of HCC cells. Therefore, TCS enhanced the drug resistance-related genes expression in MHCC97-H cells. For the following experiments, we chose the maximum-effect concentration (300 nmol/L) without cytotoxicity as a standard concentration for TCS treatment.
Triclosan promotes the clearance of sorafenib in Mhcc97-h cells MHCC97-H cells were treated with 1 μmol/L sorafenib for 12 hours before being washed and incubated in solvent control or 300 nmol/L TCS for another 12 hours. As shown in Figure 3A , sorafenib was cleared within 24 hours in cultured MHCC97-H cells, and the half-life (t1/2 value) is 9.70 ± 0.42 hours. TCS treatment promoted the clearance of sorafenib in MHCC97-H cells as the half-life (t1/2 value) is reduced to 5.43 ± 0.28 hours.
Moreover, to test the effect of TCS on sorafenib clearance in vivo, MHCC97-H subcutaneous tumor-bearing mice were administrated with sorafenib solution formulation (Sor-Sol) and then treated with solvent control or 500 μg/kg TCS. Tumor tissues were harvested, and the remaining sorafenib in tumors was examined. As shown in Figure 3B , sorafenib was completely cleared in tumor tissues at 48 hours with a half-life (t1/2 value) of 20.56 ± 0.57 hours. Treatment with 500 μg/kg TCS promoted the clearance of sorafenib in HCC tumors and decreased the half-life (t1/2 value) of sorafenib to 12.39 ± 0.77 hours.
Triclosan enhances sorafenib resistance in hcc
The interaction of TCS and sorafenib in cell or cancer models was examined. As shown in Figure 4 , despite sorafenib inhibited MHCC97-H cells proliferation in in vitro model, treatment with 300 nmol/L TCS attenuates the antitumor effect of sorafenib, as the IC 50 values of sorafenib on MHCC97-H cells elevated from 1.03 ± 0.07 to 9.64 ± 0.79 μmol/L. Next, to further confirm the effect of TCS on sorafenib's antitumor effect, patient-derived cell lines were used. As shown 
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The IC 50 values of sorafenib were increased. For in vivo subcutaneous tumors models, the tumor volumes and tumor weights of subcutaneous tumors were evaluated. As shown in Figure 6 , treatment with TCS promoted tumor growth, indicating that TCS may act as a tumor promoter, which is consistent with the previous studies. 10 Sorafenib, an antitumor drug, significantly inhibited tumor growth compared with control, as predicted. Sorafenib coupled with TCS showed less tumor suppressing effect compared with sorafenib alone, indicating that TCS reduced the antitumor effect of sorafenib.
Next, the intrahepatic MHCC97-H tumor model was established, and TCS, sorafenib, or combined treatments were performed. As shown in Figure 7A , the intrahepatic growth of HCC cells in mice liver was identified by PET/CT screening. As expected, TCS enhanced the PET imaging in liver location compared with solvent control, whereas sorafenib treatment decreased the PET imaging in liver location of mice. TCS attenuated the antitumor effect of sorafenib on intrahepatic growth of HCC cells. The PET imaging was further confirmed by liver-to-blood radioactivation examination ( Figure 7A ). Also, animals were sacrificed, and livers were collected to identify the nodules formed by HCC cells in liver organs. As shown in Figure 7B , TCS promoted the growth of HCC cells in mice livers, and the nodules formed by HCC cells were larger than those in the control group. Sorafenib treatment significantly attenuated the intrahepatic growth of HCC cells in mice's liver, and the nodules formed by HCC cells were shrinking compared with those in the control group. TCS attenuated the antitumor effect of sorafenib on intrahepatic growth of HCC cells. Liver organ images were also supported by the PET imaging of separated liver organs ( Figure 7B ). Taken together, both in vitro and in vivo data indicated that TCS enhanced the sorafenib resistance in HCC tumor models.
Discussion
Although molecular targeting agent sorafenib was considered as a new hope for patients with advanced HCC, the overall prognosis and survival are still far from satisfaction. [21] [22] [23] Due to the genetic heterogeneity of HCC, some patients are intrinsically resistant to sorafenib, whereas for some other patients, acquired resistance to sorafenib often occur during treatment. 24 Zhu et al, systemically summarized the potential mechanisms of sorafenib resistance in their recent review. 
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Triclosan enhances sorafenib resistance in hcc However, the environmental inducer of sorafenib resistance remains practically unknown. In the present work, we showed that TCS induced the expression of several drug resistancerelated genes in mice, promoted the clearance of sorafenib in both HCC cells and tumors, and enhanced the sorafenib resistance in MHCC97-H cells.
The exposure of environmental chemicals, for example, environmental poison or environmental endocrine-disrupting chemicals, remains a public health problem. 25 Certain chemicals can disrupt endocrine system and homeostasis. 25 TCS can be absorbed through human skin and oral mucosa and have been found persist in various human tissues and fluids. 26 Previously, TCS was considered as an endocrine disruptor, which promoted the progress of some endocrine-related human cancers, for example, breast cancer, similar to bisphenol A (BPA). [27] [28] [29] [30] Yueh et al showed that TCS promotes the progress of cirrhosis and HCC in mice model. 10 However, the exact role of TCS in human HCC was unknown. This work reported the roles of TCS in inducing sorafenib resistance for the first time. Drug resistance-related gene clusters chosen in this work include CYP 450, ATP-binding cassette, and other transferases. These genes mediate the clearance of chemical drugs, indicating TCS may induce the expression of drug resistancerelated genes to accelerate sorafenib clearance. Interestingly, our results also showed that TCS did not affect the expression of ALDH1A1, Apo E, ADRA2A, DPYD, COMT, TPMT, 
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Wu et al HTRA, or MTHFR, which all participate in drug resistance, but not by promoting drug metabolism or clearance. [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] These results confirmed the specificity of TCS function.
Moreover, nuclear receptors, for example, peroxisome proliferators-activated receptor (PPAR), pregnane X receptor (PXR), or constitutive androstane receptor (CAR), mediate the transcription of drug-resistance genes upon agonist activation. [40] [41] [42] [43] [44] [45] [46] Yueh et al indicated that TCS may be an agonist of PPAR, PXR, or CAR. 10 Therefore, it is valuable to reveal whether TCS interacts with nuclear receptors in the follow-up investigations.
Conclusion
Our study revealed TCS promotes the clearance of sorafenib and induces sorafenib resistance in HCC cell line and in vivo tumor models, suggesting that exposure of TCS is extremely harmful for HCC patients undergoing sorafenib chemotherapy. 
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